We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





Antibodies in Llama Blood Could Hold Key to Developing COVID-19 Vaccine

By HospiMedica International staff writers
Posted on 23 Apr 2020
Researchers from the Vlaams Institute for Biotechnology {(VIB) Ghent, Belgium} have proposed that antibodies found in the blood of the South American animal, llamas could hold the key to developing a vaccine for COVID-19. More...
The researchers discovered the llama antibodies while previously researching HIV and believe that they could help to neutralize SARS-CoV-2 that causes COVID-19.

The antibodies found in llama blood are smaller than human antibodies, but have shown to be effective against MERS and SARS, which are close relatives of the novel coronavirus that causes COVID-19. This could make it possible to use the animal-based antibodies in nanotechnology as part of a delivery of antiviral activity into humans. American researchers have earlier used llama antibodies for developing a universal flu vaccine and discovered that they work effectively on a variety of flu viruses.

In addition to focusing on the llama, researchers across the world are also looking at ferrets and hamsters for a COVID-19vaccine candidate. For instance, South Korean researchers using ferrets as animal models for testing potential COVID-19 drugs in humans have found that the disease behaves in the same way in ferrets as it does in humans. The researchers found ferrets to be good candidates for research because the anatomic proportions of the ferret’s upper and lower respiratory tracts, the density of submucosal glands in the bronchial wall and the number of generations of terminal bronchioles reproduce the condition in the human respiratory tract. Similarly, researchers in Hong Kong experienced success with Syrian hamsters after their studies showed that hamsters displayed similar effects of the COVID-19 disease.

Despite the best efforts by researchers across the world for developing a COVID-19 vaccine candidate, data indicates that a vaccine will be unavailable for use until the end of 2020 or early 2021.

Related Links:
Vlaams Institute for Biotechnology


Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Digital Color Doppler Ultrasound System
MS22Plus
IV Therapy Cart
Avalo I.V Therapy Cart
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.